NewAmsterdam wins EU ok for obicetrapib, €833m milestones
European approval of Ubeslo and Evlarco triggers new royalties and milestone payments for NewAmsterdam Pharma under its Menarini licensing deal.
Rhea-AI Filing Summary
NewAmsterdam Pharma Co N.V. (NAMS) announced that the European Commission granted marketing authorization for Ubeslo (obicetrapib 10 mg monotherapy) and Evlarco (10 mg obicetrapib plus 10 mg ezetimibe fixed-dose combination) to treat primary hypercholesterolaemia and mixed dyslipidaemia, representing the first regulatory approval of obicetrapib worldwide. The authorizations cover all EU Member States, Iceland, Liechtenstein and Norway. The approvals require ongoing safety monitoring, pharmacovigilance, risk-minimization measures and a post-authorization efficacy study using final results from the PREVAIL cardiovascular outcomes trial. Under an existing licensing agreement, Menarini holds exclusive commercialization rights for obicetrapib in Europe and manages regulatory and commercial activities there, while NewAmsterdam is entitled to tiered double-digit royalties and up to €833 million in additional clinical, regulatory and commercial milestones, including milestone payments in the mid-teens of millions of euros triggered by these EC authorizations.
Positive
- European Commission marketing authorization for Ubeslo and Evlarco grants the first regulatory approval of obicetrapib worldwide across all EU Member States plus Iceland, Liechtenstein and Norway.
- NewAmsterdam is entitled to tiered double-digit percentage royalties on Menarini’s net sales in its territory, plus up to €833 million in additional clinical, regulatory and commercial milestone payments.
- The EC approvals immediately trigger milestone payments in the mid-teens of millions of euros, providing near-term non-dilutive cash linked to obicetrapib’s commercialization.
Negative
- None.
Insights
Analyzing...
8-K Event Classification
Item 8.01 — Other Events
1 item
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Key Figures
Obicetrapib monotherapy dose: 10 mg
Fixed-dose combination components: 10 mg obicetrapib + 10 mg ezetimibe
Maximum milestone consideration: €833 million
+3 more
6 metrics
Obicetrapib monotherapy dose
10 mg
Dose in Ubeslo monotherapy approved for primary hypercholesterolaemia and mixed dyslipidaemia
Fixed-dose combination components
10 mg obicetrapib + 10 mg ezetimibe
Evlarco fixed-dose combination approved in Europe
Maximum milestone consideration
€833 million
Total potential clinical, regulatory and commercial milestone payments under Menarini licensing agreement
Triggered milestone range
Mid-teens of millions of euros
Milestones activated by EC marketing authorizations for obicetrapib and the FDC
Royalty rate range
Low double-digits to mid-twenties percent
Tiered double-digit percentage royalties on net sales in the Menarini Territory
Authorization date
September 21, 2026
Date EC granted marketing authorizations for Ubeslo and Evlarco
Key Terms
marketing authorization, primary hypercholesterolaemia, mixed dyslipidaemia, pharmacovigilance, +2 more
6 terms
marketing authorization regulatory
"the European Commission has granted marketing authorization for Ubeslo"
An official government approval that allows a drug, vaccine, or medical device to be sold and promoted in a specific country or region. Think of it as a safety and effectiveness passport issued after regulators review the product’s tests and manufacturing; for investors, receiving this authorization typically unlocks sales, revenue potential, and lower regulatory risk, while delays or denials can substantially affect a company’s value and timeline.
primary hypercholesterolaemia medical
"for patients with primary hypercholesterolaemia (heterozygous familial"
mixed dyslipidaemia medical
"or mixed dyslipidaemia, marking the first regulatory approval"
pharmacovigilance medical
"require customary post-approval safety monitoring, pharmacovigilance activities"
Pharmacovigilance is the process of monitoring and assessing the safety of medicines after they are on the market, ensuring that any side effects or risks are identified and managed. For investors, it matters because it helps ensure that pharmaceutical companies maintain safe products, which can influence a company’s reputation, regulatory approval, and financial stability over time.
fixed-dose combination medical
"Evlarco (10 mg obicetrapib plus 10 mg ezetimibe fixed-dose combination"
A fixed-dose combination is a single medication that contains two or more active drugs combined in set proportions, like a combo meal that packages complementary items into one order. For investors it matters because such products can improve patient convenience and adherence, streamline manufacturing and marketing, and create distinct regulatory and patent opportunities or risks that affect a drug’s market size, pricing power, and long-term revenue potential.
cardiovascular outcomes trial medical
"the Company’s PREVAIL cardiovascular outcomes trial, a placebo-controlled"
A cardiovascular outcomes trial is a large clinical study designed to see whether a medicine or intervention affects major heart-related events such as heart attacks, strokes, hospitalization for heart failure, or death. Think of it as a long road-test that measures real-world safety and benefit for the heart rather than just short-term lab results. Investors watch these trials because their results can change a product’s approval, labeling, sales potential, and legal risk, and thus a company’s valuation.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What regulatory milestone did NewAmsterdam Pharma (NAMS) report?
NewAmsterdam reported that the European Commission granted marketing authorization for Ubeslo and Evlarco to treat primary hypercholesterolaemia and mixed dyslipidaemia, representing the first regulatory approval of obicetrapib worldwide and applying across all EU Member States plus Iceland, Liechtenstein and Norway.
Which products of NAMS were approved by the European Commission?
The European Commission approved Ubeslo (obicetrapib 10 mg monotherapy) and Evlarco (10 mg obicetrapib plus 10 mg ezetimibe fixed-dose combination) for patients with primary hypercholesterolaemia, including HeFH and non-familial forms, and for patients with mixed dyslipidaemia.
How does the Menarini partnership affect NewAmsterdam Pharma’s economics?
Under a licensing agreement, Menarini has exclusive commercialization rights for obicetrapib in Europe and manages regulatory and commercial activities, while NewAmsterdam earns tiered double-digit percentage royalties on net sales in the Menarini Territory plus potential milestone payments.
What is the potential milestone value for NAMS from the Menarini deal?
NewAmsterdam may receive up to €833 million in additional clinical, regulatory and commercial milestone payments from Menarini, including milestone payments in the mid-teens of millions of euros that are triggered by the European Commission’s marketing authorizations for obicetrapib and the FDC.
What post-approval obligations are tied to obicetrapib’s EU authorization?
The authorizations require post-approval safety monitoring, pharmacovigilance activities and risk-minimization measures, as well as a post-authorization efficacy study for which NewAmsterdam must submit final results from the PREVAIL cardiovascular outcomes trial evaluating obicetrapib.
Who is responsible for obicetrapib commercialization in Europe for NAMS?
Menarini is responsible for regulatory interactions and commercialization activities for obicetrapib throughout Europe under its licensing agreement with NewAmsterdam, and holds exclusive commercialization rights in the Menarini Territory.
AI-generated analysis. How Rhea-AI works. Not financial advice.
